Compare Incyte Corporation (INCY) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tractor Supply Co — how do they compare? Incyte Corporation trades at $113.77 (market cap $22.85B), while Tractor Supply Co trades at $33.59 (market cap $17.44B). The key difference: Incyte Corporation is the larger of the two by market cap, and Tractor Supply Co pays a 2.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Tractor Supply Co for 88 Days on average.
| INCY | TSCO | |
|---|---|---|
Market Cap | $22.85B | $17.44B |
Volume | 1,927,029 | 10,598,723 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $56.37 |
52-Week Low | $83.80 | $29.14 |
Typical Hold Time | 33 Days | 88 Days |
Enterprise Value | $18.35B | $23.76B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Tractor Supply (TSCO) trades at $32.52, up 0.71% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported revenue of $15.52B in 2025, with a net income margin of 6.42% and a P/E ratio of 17.44. Recent earnings misses and a dividend streak under scrutiny are balanced by expansion efforts, including a new distribution center in Idaho.
The outlook is mixed; analyst consensus is a $36.76 price target with a near-even split between buy and hold ratings. Risks include consecutive earnings misses and competitive pressures, but the company's strong ROE of 39.51% and consistent dividend history offer potential for patient investors amid cyclical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
